Evidence map›Paper›PMID 30636030›Full record

ArticleJournal of biophotonics2019

Widefield fluorescence lifetime imaging of protoporphyrin IX for fluorescence-guided neurosurgery: An ex vivo feasibility study.

Mikael T Erkkilä, Bianca Bauer, Nancy Hecker-Denschlag, Maria J Madera Medina, Rainer A Leitgeb, Angelika Unterhuber, Johanna Gesperger, Thomas Roetzer, Christoph Hauger, Wolfgang Drexler and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of biophotonics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. What scans we will read: imaging instrumentation trends in clinical oncology.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Mikael T ErkkiläCenter for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-5314-1486
Bianca BauerAdvanced Development Microsurgery, Carl Zeiss Meditec AG, Oberkochen, Germany.
Nancy Hecker-DenschlagAdvanced Development Microsurgery, Carl Zeiss Meditec AG, Oberkochen, Germany.
Maria J Madera MedinaAdvanced Development Microsurgery, Carl Zeiss Meditec AG, Oberkochen, Germany.
Rainer A LeitgebCenter for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
Angelika UnterhuberCenter for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-1251-3001
Johanna GespergerInstitute of Neurology, General Hospital and Medical University of Vienna, Vienna, Austria.
Thomas RoetzerInstitute of Neurology, General Hospital and Medical University of Vienna, Vienna, Austria.
Christoph HaugerAdvanced Development Microsurgery, Carl Zeiss Meditec AG, Oberkochen, Germany.
Wolfgang DrexlerCenter for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
Georg WidhalmDepartment of Neurosurgery, General Hospital and Medical University of Vienna, Vienna, Austria.
Marco AndreanaCenter for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-8212-0545
Carl Zeiss (Germany) · DEMedical University of Vienna · ATVienna General Hospital · ATChristian Doppler Laboratory for Thermoelectricity · AT

Funding

Carl Zeiss Meditec AGH2020 Marie Skłodowska-Curie Actions 721766
6 · The paper itself

Abstract

Achieving a maximal safe extent of resection during brain tumor surgery is the goal for improved patient prognosis. Fluorescence-guided neurosurgery using 5-aminolevulinic acid (5-ALA) induced protoporphyrin IX has thereby become a valuable tool enabling a high frequency of complete resections and a prolonged progression-free survival in glioblastoma patients. We present a widefield fluorescence lifetime imaging device with 250 mm working distance, working under similar conditions such as surgical microscopes based on a time-of-flight dual tap CMOS camera. In contrast to intensity-based fluorescence imaging, our method is invariant to light scattering and absorption while being sensitive to the molecular composition of the tissue. We evaluate the feasibility of lifetime imaging of protoporphyrin IX using our system to analyze brain tumor phantoms and fresh 5-ALA-labeled human tissue samples. The results demonstrate the potential of our lifetime sensing device to go beyond the limitation of current intensity-based fluorescence-guided neurosurgery.

Indexed as

Neurosurgical ProceduresOptical ImagingSurgery, Computer-AssistedBrainFeasibility StudiesHumansPhantoms, ImagingProtoporphyrinsprotoporphyrin IXProtoporphyrinsfluorescence guided surgeryfluorescence lifetime imagingneurooncologyphotodynamic diagnosistime of flight camera

Identifiers

PMID30636030
PMCPMC7065606
OpenAlexW2909013976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.